Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
Sitagliptin showed greater glycemic efficacy over dapagliflozin when added onto existing therapy.
Read More »Patients With T2D, Mild Renal Impairment Can Benefit From A DPP-4 Inhibitor
Dipeptidyl Peptidase-4 Inhibitors and Incidence of Inflammatory Bowel Disease
Prolonged use of medication increases risk of bowel condition, but exact cause yet to be determined.
Read More »Understanding The Gap Between Efficacy In Randomized Trials And Effectiveness In Real-World Use Of GLP-1RA and DPP-4 Therapies
Patients are not seeing the expected results because of medication adherence.
Read More »Greater HbA1c Reduction with DPP4 Inhibitor, AGI Combination
Additive glucose-lowering effect of a dipeptidyl peptidase-4 (DPP4) inhibitor and an alpha-glucosidase inhibitor (AGI) might be beneficial in patients with T2DM.
Read More »Heart Failure Warning Added to the DPP-4 Inhibitor Class of Drugs
Increased cardio risk of Saxagliptin found during trial prompts FDA decision.
Read More »DPP-4 Inhibitor Safe & Effective for Type 2’s With CVD
The DPP-IV inhibitor sitagliptin was safe and effective over 3 years for adults aged at least 75 years who had well-controlled type 2 diabetes and cardiovascular disease, findings from an analysis of TECOS study data show.
Read More »DPP-4 Inhibitor Can Provide Vascular Protection
We know from previous studies that obesity and type 2 diabetes are associated with vascular stiffening and the development of cardiovascular disease.
Read More »Effect of Sitagliptin on Kidney Function and Cardiovascular Outcomes
A DPP-4 inhibitor can help to prevent kidney function and did not have any negative cardiovascular effects.
Read More »A Review of DPP-4 Inhibitors
DPP-4 Inhibitors offer some advantages over existing oral options for the management of type 2 diabetes such as a negligible risk of hypoglycemia compared with sulfonylureas and, in general, a weight-neutral profile.
Read More »DPP-4 Inhibitors Charts & Dosing Information for Special Populations
Forms, dosages and dosing considerations for pregnancy, breastfeeding, hepatic and renal.
Read More »